Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Regdanvimab in Mild to Moderate COVID-19
KCT0006254Phase 2Completed
- Sponsor
- Celltrion
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of regdanvimab in coronavirus disease 2019 (COVID-19), sponsored by Celltrion. Started Feb 2021; status: completed.
02
Drugs
regdanvimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on KCT0006254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006254.